These 5 investors are betting on helping you live longer and better

Analysts estimate that the market for “delaying human death” could be worth $610 billion by 2025. But that doesn’t sit well with Christian Angermayer, who co-founded Cambrian BioPharma and Rejuveneron, and whose family office Apeiron Investment Group has a special interest in expanding longevity.
“This is a nonsensical, imaginary number that is almost entirely made up by the cosmetics and supplements industry,” Angermayer said of the $610 billion estimate. In his view, the total addressable market of longevity-related plays is both smaller and potentially much lar

リンク元